Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 2959-2968

  De Oliveira, Camila I ^a   Wunderlich, Gerhard ^a   Levitus, Gabriela ^a   Soares, Irene S ^b   Rodrigues, Mauricio M ^b   Tsuji, Moriya ^b   Del Portillo, Hernando A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

DNA vaccines; Merozoite surface protein 1; Plasmodium vivax

Indexed keywords

DNA VACCINE; MALARIA VACCINE; MEMBRANE PROTEIN; PLASMID DNA; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; MEROZOITE; MOUSE; NONHUMAN; PARASITE; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN ANALYSIS; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; COS CELLS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, VIVAX; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PLASMIDS; PLASMODIUM VIVAX; VACCINES, DNA;

EID: 0033529615     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00176-0     Document Type: Article

References (42)

1. David P.H., del Portillo H.A., Mendis K.N. Plasmodium vivax malaria: parasite biology defines potential targets for vaccine development. Biol Cell. 64:1988;251-260.
2. Galinski M.R., Barnwell J.W. Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for malaria vaccine development. Parasitol Today. 12:1996;20-29.
3. Phillips E.J., Keystone J.S., Kain K.C. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 23:1996;1171-1173.
4. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol. 15:1997;617-648.
5. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA. 91:1994;9866-9870.
6. Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology. 84:1995;173-176.
7. Angus C.W., Klivington D., Wyman J., Kovacks J.A. Nucleic acid vaccination against Toxoplasma gondii in mice. J Eukaryot Microbiol. 43:1996;117S.
8. Waine G.J., Yang W., Scott J.C., McManus D.P., Kalinna B.H. DNA-based vaccination using Schistosoma japonicum (Asian blood-fluke) genes. Vaccine. 15:1997;846-848.
9. d'Oliveira C., Feenstra A., Vos H., Osterhaus A.D., Shiels B.R., Cornelissen A.W., Jongejan F. Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems. Vaccine. 15:1997;1796-1804.
10. Costa F., Franchin G., Pereira-Chioccola V.L., Ribeirao M., Schenkman S., Rodrigues M.M. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine. 16:1998;768-774.
11. + cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med. 183:1996;1739-1746.
12. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., Lyon J.A. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol. 159:1997;6112-6119.
13. Becker S.I., Wang R., Hedstrom R.C., Aguiar J.C., Jones T.R., Hoffman S.L., Gardner M.J. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines. Infect Immun. 66:1998;3457-3461.
14. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., Jones T.R., Hobart P., Margalith M., Ng J., Weiss W.R., Sedegah M., de Taisne C.A., Norman J., Hoffman S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
15. Holder A.A. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy. 41:1988;72-97.
16. Holder A.A., Freeman R.R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature. 294:1981;361-364.
17. + T cells. J Immunol. 159:1997;3400-3411.
18. Daly T.M., Long C.A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 155:1995;236-243.
19. Hall R., Hyde J.E., Goman M., Simmons D.L., Hope I.A., Mackay M., Scaife J., Merkli B., Richle R., Stocker J. Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature. 311:1984;379-382.
20. Siddiqui W.A., Tam L.Q., Kramer K.J., Hui G.S., Case S.E., Yamaga K.M., Chang S.P., Chan E.B., Kan S.C. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA. 84:1987;3014-3018.
21. Ling I.T., Ogun S.A., Holder A.A. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:1994;63-67.
22. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A., Miller L.H., Kaslow D.C. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med. 1:1995;325-332.
23. Cheung A., Leban J., Shaw A.R., Merkli B., Stocker J., Chizzolini C., Sander C., Perrin L.H. Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc Natl Acad Sci USA. 83:1986;8328-8332.
24. Perrin L.H., Simitsek P., Fasani-Ghersa P. Asexual blood stage vaccines: from merozoites to peptides. Trans R Soc Trop Med Hyg. 83:(Suppl):1989;53-56.
25. Perera K.L., Handunnetti S.M., Holm I., Longacre S., Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun. 66:1998;1500-1506.
26. del Portillo H.A., Longacre S., Khouri E., David P.H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci USA. 88:1991;4030-4034.
27. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 74:1977;5463-5467.
28. Levitus G., Mertens F., Speranca M.A., Camargo L.M., Ferreira M., del Portillo H.A. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax. Am J Trop Med Hyg. 51:1994;68-76.
29. Soares I.S., Levitus G., Souza J.M., Del Portillo H.A., Rodrigues M.M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun. 65:1997;1606-1614.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
31. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing a principle of protein dye binding. Anal Biochem. 72:1976;248-254.
32. + T cells using an ELISPOT assay. J Immunol Methods. 181:1995;45-54.
33. Levitus G., Mertens F., Kirchgatter K., Oliveira S.G., del Portillo H.A. Plasmodium vivax: epitope mapping of monoclonal antibodies against the N-terminal region of the merozoite surface protein 1. Behring Inst Mitt. 99:1997;107-111.
34. Good M.F., Kaslow D.C., Miller L.H. Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol. 16:1998;57-87.
35. Tian J.H., Miller L.H., Kaslow D.C., Ahlers J., Good M.F., Alling D.W., Berzofsky J.A., Kumar S. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J Immunol. 157:1996;1176-1183.
36. Mancilla L.I., Levitus G., Kirchgatter K., Mertens F., Herrera S., del Portillo H.A. Plasmodium vivax: dimorphic DNA sequences from the MSP-1 gene code for regions that are immunogenic in natural infections. Exp Parasitol. 79:1994;148-158.
37. Zavala F., Masuda A., Graves P.M., Nussenzweig V., Nussenzweig R.S. Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol. 135:1985;2790-2793.
38. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., Hashiro C.Q., Nikaido C.M., Gibson H.L., Lee-Ng C.T., Barr P.J., Yokota B.T., Hui G.S. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun. 64:1996;253-261.
39. 19) and their role in immunity to malaria. Parasite Immunol. 20:1998;263-278.
40. Grifantini R., Finco 0., Bartolini E., Draghi M., Del Giudice G., Kocken C., Thomas A., Abrignani S., Grandi G. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur J Immunol. 28:1998;1225-1232.
41. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 336:1997;86-91.
42. Egan A., Waterfall M., Pinder M., Holder A., Riley E. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun. 65:1997;3024-3031.